News EMA advisors say CSL's Tavneos should be pulled from sale Pressure is building on Amgen to withdraw rare disease therapy Tavneos, after the CHMP recommended its marketing authorisation by revoked in the EU.
News Amgen baulks at FDA request to withdraw Tavneos Amgen confirmed on its fourth-quarter results call that it has resisted a request to pull Tavneos for ANCA-associated vasculitis from the US market.
News EMA looks into 'data integrity' issue with Amgen's Tavneos Concerns about efficacy data in the main trial behind the approvals of Amgen and CSL Vifor's Tavneos have triggered a review in the EU.
R&D Cassava’s Alzheimer’s drug nears P3 readout, but SEC scandal... Cassava is advancing simufilam through a pivotal phase 3 trial, despite lingering controversy from a SEC investigation.
R&D Challenges and opportunities in synthetic clinical trials Of the many changes coming to clinical trials, one of the biggest potential paradigm shifts on the horizon is the elimination of placebo groups in some trials in favour of synthetic control
Digital Transitioning PROs from paper to digital: Maintaining data i... Patient-reported outcomes (PROs) provide important insights for clinical trials.
Oncology On looking to a future multiomics approach for CDx, with Jan... The pharmaphorum podcast caught up with Jane Li, VP and general manager for companion diagnostics at Thermo Fisher Scientific, following ESMO 2026.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.